Published in Obesity and Diabetes Week, April 11th, 2005
QuatRx licensed the compounds from EndoChem, Inc., a biotechnology company headquartered in Berkeley, California. This new compound, called QRX-431, is designed to treat lipid abnormalities involving LDL-cholesterol and Lp(a), both recognized as risk factors for cardiovascular disease.
The compound may potentially be used as a single agent or in combination with currently available lipid-lowering drugs, and also has potential in the treatment of obesity. When approved, QRX-431...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week